Watch CRMD. Know when insiders buy.
One email the day a filing lands. Free.
CRMD
CorMedix Inc.
7.96
−0.17 −2.09%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · shorts 37
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $620.4MP/E 3.9DIV YIELD —FCF YIELD 40.36%REV TTM $462.2M +280.5%NET INCOME $187.2M +265.9%NET CASH —52W 6.25 – 13.09SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $101.9M | +156.5% | 75.7% | $42.9M | $26M | +31.1% | 0.29 | $86.2M | $561K | $85.7M | Aug 13 |
| Q1 2026 · Mar 31 | $127.4M | +226.1% | 82.5% | $63.7M | $38.6M | +87.0% | 0.43 | $42.4M | $729K | $41.7M | May 14 |
| Q4 2025 · Dec 31derived | $128.6M | +312.1% | 83.4% | $59.1M | $14M | +4.1% | 0.07 | $94.5M | $1.7M | $92.7M | Mar 5 |
| Q3 2025 · Sep 30 | $104.3M | +810.2% | 89.3% | $51.3M | $108.6M | — | 1.26 | $30.9M | $506K | $30.4M | Nov 12 |
| Q2 2025 · Jun 30 | $39.7M | +4829.4% | 95.3% | $19.5M | $19.8M | — | 0.28 | $30M | $24K | $30M | Aug 13 |
| Q1 2025 · Mar 31 | $39.1M | — | 95.9% | $20.1M | $20.6M | — | 0.30 | $19.7M | $10K | $19.7M | May 14 |
| Q4 2024 · Dec 31derived | $31.2M | — | 96.2% | $12.9M | $13.5M | — | 0.24 | −$5.6M | $10K | −$5.6M | Mar 5 |
| Q3 2024 · Sep 30 | $11.5M | — | 94.0% | −$3.3M | −$2.8M | — | -0.05 | −$13.6M | $10K | −$13.7M | Nov 12 |
| Q2 2024 · Jun 30 | $806K | — | 36.8% | −$15.3M | −$14.2M | — | -0.25 | −$14M | $35K | −$14.1M | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$16.7M | −$14.5M | — | -0.25 | −$17.3M | $61K | −$17.4M | May 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$15.7M | −$14.8M | — | -0.26 | −$10.7M | $296K | −$11M | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | −$10.5M | −$9.7M | — | -0.17 | −$8.7M | $10K | −$8.7M | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $311.7M | 88.5% | $150.1M | $163.1M | 52.3% | 2.04 | $175M | $2.3M | $172.8M | — | — |
| FY2024 · to Dec 31 | $43.5M | 92.7% | −$22.4M | −$17.9M | -41.2% | -0.30 | −$50.6M | $116K | −$50.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$49M | −$46.3M | — | -0.91 | −$38.4M | $327K | −$38.7M | — | — |
| FY2022 · to Dec 31 | $65K | 94.3% | −$30.6M | −$29.7M | -45409.9% | -0.74 | −$24.4M | $219K | −$24.6M | — | — |
| FY2021 · to Dec 31 | $191K | 22.0% | −$29.4M | −$28.2M | -14774.7% | -0.75 | −$21.2M | $1.4M | −$22.6M | — | — |
| FY2020 · to Dec 31 | $239K | 14.4% | −$27.2M | −$22M | -9207.7% | -0.77 | −$22M | $113K | −$22.1M | — | — |
Every number comes from CorMedix Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.